ClinicalTrials.gg
CompletedNCT00641693Updated Jan 24, 2011

Assess the Efficacy and Safety of Rhinocort Aqua

A Phase 2 interventional study of Budesonide and Budesonide in Allergic Rhinitis, sponsored by AstraZeneca. Completed. Open to participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2011-01-24.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
650
Allocation
Randomized
Ages
2 Years to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies in Rhinitis, Allergic by AstraZeneca — none open to participants now, none under way, none of them phase 3. Rhinitis, Allergic · AstraZeneca.

Planned enrollment
2nd of 12
650 · median 205
Started
2004
with 1 other
Phase 2
3 of 12
none open now
Registered
6th of 12
by date

Among the 12 studies in Rhinitis, Allergic by AstraZeneca, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2004, is one of 3 in phase 2, and was the 6th registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

None of the 12 studies in Rhinitis, Allergic by AstraZeneca is open now. The open studies under Rhinitis, Allergic, anywhere →

Where they have run

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 2 Years to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Rhinitis, Allergic by AstraZeneca as a file.
02

Study summary

The purpose of this study is to compare Rhinocort with placebo in pediatric subjects aged 2-5 years with allergic rhinitis to study effects on nasal symptoms such as sneezing, runny and stuffy noses.

03

Conditions studied

  • Allergic Rhinitis

Keywords

  • Allergic rhinitis
  • Paediatric
  • Nasal symptoms
  • Congestion
  • Rhinorrhea
  • Sneeze
  • budesonide
  • Rhinocort AQUA
04

Who can participate

Ages eligible
2 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In the opinion of the investigator, is a candidate for treatment with nasal based on a history of either a) inadequate control of symptoms with antihistamines, decongestants and/or immunotherapy, or b) prior successful treatment with nasal steroids.
  • A documented history of allergic rhinitis and a positive response to a skin prick test at Visit 1 or within the last 12 months for allergens that must be present in the subject's environment for the duration of the study.
  • At randomisation having nasal symptom scores as defined by the protocol.

Exclusion criteria

Exclusion Criteria:

  • Primary or secondary adrenal insufficiency
  • Nasal candidiasis, rhinitis medicamentosa, acute or chronic sinusitis, influenza, upper respiratory tract infection or structural abnormalities of the nose (e.g., septal deviation, nasal polyps) symptomatic enough to cause significant nasal obstruction as judged by the investigator.
  • A diagnosis of asthma requiring treatment as specifies in the protocol.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
650 participants (estimated)

Study arms

  • Experimental
    1

    Nasal Spray

    Drug: Budesonide

  • Placebo comparator
    2

    Drug: Placebo

Interventions

  • 16mg Nasal Spray

    Also known as: Rhinocort AQUA

  • 32mg Nasal Spray

    Also known as: Rhinocort AQUA

  • 64mg Nasal Spray

    Also known as: Rhinocort AQUA

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. To compare Rhinocort with placebo to compare effects on nasal symptoms such as sneezing, runny and stuffy noses as assessed by caregivers.

    Time frame: At 2 weeks

Secondary outcomes

  1. Safety assessment via adverse events and clinical measurements

    Time frame: At 1 & 2 weeks

  2. To assess efficacy of Rhinocort via the physician and caregivers assessments

    Time frame: At 2 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of May 2005 and a completion of May 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2008
First posted
Mar 24, 2008
Start
Apr 2004
Primary completionActual
May 2005
CompletionActual
May 2005
Last update
Jan 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00641693
Lead sponsor
AstraZeneca
First posted
Mar 24, 2008
Start date
Apr 2004
Primary completion
May 2005
Completion
May 2005
Last update
Jan 24, 2011

Study contacts

Liza O'Dowd, MD
study director · AstraZeneca
Bertil Andersson
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion